Sugi Predict

Sugi Predict / Targets / C1R

C1R

Complement C1r subcomponent · P00736 · C1R on Sugi Atlas →

5,585 patent compounds predicted against C1R, 3,437 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3453116 SCHEMBL3453116 0.67 19/20
SCHEMBL913450 SCHEMBL913450 1.00 15/20
SCHEMBL3452308 SCHEMBL3452308 0.69 15/20
SCHEMBL3453097 SCHEMBL3453097 0.71 13/20
SCHEMBL3453269 SCHEMBL3453269 0.52 13/20
SCHEMBL3452791 SCHEMBL3452791 0.60 12/20
SCHEMBL3452631 SCHEMBL3452631 0.47 12/20
SCHEMBL3453029 SCHEMBL3453029 0.70 11/20
SCHEMBL3453537 SCHEMBL3453537 0.70 11/20
SCHEMBL3452177 SCHEMBL3452177 0.67 11/20
SCHEMBL3452889 SCHEMBL3452889 0.65 11/20
SCHEMBL3452122 SCHEMBL3452122 0.63 11/20
SCHEMBL916155 SCHEMBL916155 0.55 11/20
SCHEMBL3453309 SCHEMBL3453309 0.50 11/20
SCHEMBL3453106 SCHEMBL3453106 0.48 11/20
SCHEMBL3452733 SCHEMBL3452733 0.46 11/20
SCHEMBL3453288 SCHEMBL3453288 0.46 11/20
SCHEMBL914556 SCHEMBL914556 0.72 10/20
SCHEMBL914419 SCHEMBL914419 0.70 10/20
SCHEMBL3453634 SCHEMBL3453634 0.69 10/20

Clinical trials — most relevant to C1R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions PHASE4COMPLETED
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE PHASE4COMPLETED
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema PHASE2/PHASE3COMPLETED
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema PHASE3COMPLETED
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks PHASE3COMPLETED
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks PHASE3COMPLETED
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks PHASE3COMPLETED
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) PHASE3RECRUITING
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation PHASE3COMPLETED
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks PHASE3RECRUITING
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema PHASE3COMPLETED
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) PHASE3COMPLETED
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis PHASE2COMPLETED
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N PHASE2COMPLETED
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation PHASE1COMPLETED
Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects PHASE1COMPLETED
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia PHASE1WITHDRAWN
CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60% PHASE1UNKNOWN
First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers PHASE1COMPLETED
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322) nanRECRUITING
Complement C5a Receptors in Hidradenitis Suppurativa nanCOMPLETED
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients nanUNKNOWN
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome nanCOMPLETED
Complement Activation in the Lysosomal Storage Disorders nanWITHDRAWN
Effect of Platelet Storage on Complement Activation nanUNKNOWN
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis nanCOMPLETED
Complement and Graft-versus-host Disease nanCOMPLETED
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease nanCOMPLETED
Transcriptome and Metabolic Analyses of CHAPLE Disease nanUNKNOWN
DKK-3 rs11544814 and CFH rs10737680 Polymorphism and Protein Levels With Non Surgical Periodontal Therapy in Periodontitis Patients With and Without CAD nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a C1R binder may also engage these)

ProteinNameSimilarity
Q5R1W3 — 1.000 Q5R1W3 →
Q8CFG9 — 1.000 Q8CFG9 →
Q5R544 — 1.000 Q5R544 →
Q4R577 — 1.000 Q4R577 →
Q8CG16 — 1.000 Q8CG16 →
Q69DK8 — 0.999 Q69DK8 →
Q8CFG8 — 0.994 Q8CFG8 →
Q6IE64 — 0.994 Q6IE64 →
Q6P6T1 — 0.993 Q6P6T1 →
P11214 — 0.992 P11214 →
O57382 — 0.992 O57382 →
TLL1 Tolloid-like protein 1 0.991 landscape →
P49150 — 0.991 P49150 →
Q9GLP2 — 0.991 Q9GLP2 →
F10 Coagulation factor X 0.990 landscape →
Q2F9P2 — 0.990 Q2F9P2 →
Q58L93 — 0.990 Q58L93 →
Q5E9Z2 — 0.989 Q5E9Z2 →
P70375 — 0.989 P70375 →
TMPRSS15 Enteropeptidase 0.989 landscape →
Q90WD8 — 0.989 Q90WD8 →
Q63207 — 0.989 Q63207 →
P79953 — 0.988 P79953 →
Q0VCX1 — 0.988 Q0VCX1 →
P98119 — 0.988 P98119 →
Q20176 — 0.987 Q20176 →
P98063 — 0.987 P98063 →
Q28278 — 0.987 Q28278 →
Q5G266 — 0.987 Q5G266 →
Q62381 — 0.987 Q62381 →